158 related articles for article (PubMed ID: 16321834)
1. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.
Gutiérrez A; Rodríguez J; Martínez J; Amezaga R; Ramos R; Galmes B; Bea MD; Ferrer J; Pons J; Sampol A; Morey M; Duran MA; Raurich J; Besalduch J
Leuk Lymphoma; 2006 Jan; 47(1):111-5. PubMed ID: 16321834
[TBL] [Abstract][Full Text] [Related]
2. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
Winkler U; Jensen M; Manzke O; Schulz H; Diehl V; Engert A
Blood; 1999 Oct; 94(7):2217-24. PubMed ID: 10498591
[TBL] [Abstract][Full Text] [Related]
4. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
5. Severe infusion reaction, anti-rituximab antibodies and lymphoma.
Kidoguchi K; Kubota Y; Kusaba K; Kizuka-Sano H; Yamaguchi K; Nishioka A; Yokoo M; Ando T; Kojima K; Kimura S
QJM; 2020 Apr; 113(4):273-274. PubMed ID: 31702763
[No Abstract] [Full Text] [Related]
6. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.
Wu Y; Jia Y; Xu J; Shuai X; Wu Y
J Clin Pharm Ther; 2013 Jun; 38(3):249-53. PubMed ID: 23506410
[TBL] [Abstract][Full Text] [Related]
7. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-induced tumor progression: does it really happen?
Ozguroglu M; Turna H
Med Oncol; 2004; 21(2):205-6. PubMed ID: 15299193
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
12. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
Byrd JC; Waselenko JK; Maneatis TJ; Murphy T; Ward FT; Monahan BP; Sipe MA; Donegan S; White CA
J Clin Oncol; 1999 Mar; 17(3):791-5. PubMed ID: 10071268
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.
Bienvenu J; Chvetzoff R; Salles G; Balter C; Tilly H; Herbrecht R; Morel P; Lederlin P; Solal-Celigny P; Audhuy B; Christian B; Gabarre J; Casasnovas O; Marit G; Sebban C; Coiffier B;
Hematol J; 2001; 2(6):378-84. PubMed ID: 11920277
[TBL] [Abstract][Full Text] [Related]
15. Complement activation plays a key role in the side-effects of rituximab treatment.
van der Kolk LE; Grillo-López AJ; Baars JW; Hack CE; van Oers MH
Br J Haematol; 2001 Dec; 115(4):807-11. PubMed ID: 11843813
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
Ansell SM; Witzig TE; Kurtin PJ; Sloan JA; Jelinek DF; Howell KG; Markovic SN; Habermann TM; Klee GG; Atherton PJ; Erlichman C
Blood; 2002 Jan; 99(1):67-74. PubMed ID: 11756154
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Niitsu N; Kohuri M; Higashihara M; Bessho M
Cancer Sci; 2006 Sep; 97(9):933-7. PubMed ID: 16805825
[TBL] [Abstract][Full Text] [Related]
19. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
20. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
